Advertisement

Digestive Diseases and Sciences

, Volume 42, Issue 10, pp 2111–2115 | Cite as

Metronidazole Resistance Reduces Efficacy of Triple Therapy and Leads to Secondary Clarithromycin Resistance

  • Martin J. M. Buckley
  • Hua-Xiang Xia
  • Denise M. Hyde
  • Conor T. Keane
  • Colm A. O'Morain
Article

Abstract

There has been a significant increase in theprevalence of H. pylori resistance to metronidazole inrecent years, while clarithromycin resistance is stillrelatively rare. In this study we assessed: (1) the effect of primary H. pylori resistance tometronidazole and clarithromycin on the clinicalefficacy of a one-week regimen consisting of omeprazole,metronidazole, and clarithromycin; and (2) the rate of acquisition of secondary antimicrobialresistance after treatment failure. Eighty-sevenpatients with duodenal ulceration or nonulcer dyspepsiawere included in the study. The primary metronidazoleand clarithromycin resistance rates were 35.6% and3.4%, respectively (all three pretreatmentclarithromycin resistant strains had concurrentmetronidazole resistance). H. pylori was eradicated in81.6% of patients. The eradication rate for fullysensitive isolates was 98.2% (55/56) but wassignificantly reduced to 57.1% (16/28) for isolates thatwere resistant to metronidazole alone and 0% (0/3) incases of dual resistance (P < 0.001). Secondaryresistance to clarithromycin was acquired in 58.3% ofcases of treatment failure. In areas of high prevalenceof primary metronidazole resistance, this is asignificant cause of treatment failure with this tripletherapy regimen. This leads to the selection of strainswith dual resistance that are difficult to eradicate andmay contribute to an increase in the prevalence of clarithromycin resistance. In such areas analternative first-line treatment should beprescribed.

HELICOBACTER PYLORI ANTIMICROBIAL RESISTANCE METRONIDAZOLE CLARITHROMYCIN PROTON PUMP INHIBITOR 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Coghlan JG, Gilligan D, Humphries H, McKenna D, Dooley C, Sweeney E, Keane C, O'Morain C: Campylobacter pylori and recurrence of duodenal ulcers—a 12 month follow-up study. Lancet 2:109-111, 1987Google Scholar
  2. 2.
    Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, Phillips M2, Waters TE, Sanderson CR: A prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2:1437-1442, 1988Google Scholar
  3. 3.
    Logan RPH, Gummett PA, Misiewicz JJ, Karim QM, Walker MM, Baron JH: One week's anti-Helicobacter pylori treatment for duodenal ulcer. Gut 35:15-18, 1994Google Scholar
  4. 4.
    Hosking SW, Ling TKW, Chung SCS, et al: Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment. Lancet 343:508-510, 1994Google Scholar
  5. 5.
    Penston JG: Review article: Helicobacter pylori eradication—understandable caution but no excuse for inertia. Aliment Pharmacol Ther 8:369-389, 1994Google Scholar
  6. 6.
    O'Riordan T, Mathai E, Tobin E, McKenna D, Keane C, Sweeney E, O'Morain C: Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut 31:999-1002, 1990Google Scholar
  7. 7.
    O'Connor HJ: Eradication of Helicobacter pylori: Therapies and clinical implications. Postgrad Med J 102:493-496, 1992Google Scholar
  8. 8.
    Graham DY, Lew GM, Malaty HM, Evans DG, Evans DG Jr, Klein PD, Alpert LC, Genta RM: Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102:493-496, 1992Google Scholar
  9. 9.
    Noach LA, Lagenberg WL, Bertola MA, Dankert J, Tytgat GNJ: Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 26:321-327, 1994Google Scholar
  10. 10.
    Bell GD, Powell K, Burridge SM, Pallecaros A, Jones PH, Gant PW, Harrison G, Trowell JE: Experience with “triple” anti-Helicobacter pylori eradication therapy: Side-effects and importance of testing pre-treatment bacterial isolates for metronidazole resistance. Aliment Pharmacol Ther 6:427-435, 1992Google Scholar
  11. 11.
    Noach LA, Bertola MA, Schwartz MP, Rauws EAJ, Tytgat GNJ: Treatment of Helicobacter pylori infection: An evaluation of various therapeutic trials. Eur J Gastroenterol Hepatol 6:585-591, 1994Google Scholar
  12. 12.
    Xia HX, Daw MA, Beattie S, Keane CT, O'Morain CA: The influence of metronidazole resistance on triple therapy for Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol 102:A947, 1992 (abstract)Google Scholar
  13. 13.
    Glupcznski Y, Burette A: Drug therapy for Helicobacter pylori infection: Problems and pitfalls. Am J Gastroenterol 85:1545-1551, 1990Google Scholar
  14. 14.
    Megraud F, Boyanova L, Lamouliatte H: Activity of lansoprazole against H. pylori. Lancet 337(1):1486, 1991 (letter)Google Scholar
  15. 15.
    Unge P, Gad A, Gnarpe H, Olsson J: Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis. Scand J Gastroenterol 24(suppl 167):49-54, 1989Google Scholar
  16. 16.
    Louw JA, Zak J, Jaskiewicz K, Lucke W, LeRoux E, Winter T, Lastouica A, Marks IN: Omeprazole may clear but does not eradicate H. pylori. Eur J Gastroenterol Hepatol 4:481-485, 1992Google Scholar
  17. 17.
    McNulty CAM, Dent JC, Ford GA, Wilkinson SP: Inhibitory antimicrobial concentrations against H. pylori in gastric mucosa. J Antimicrob Chemother 22:727-738, 1988Google Scholar
  18. 18.
    Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, Stratton CW, Drnec J, Prokocimer P, Siepman N: Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomised double-blind trial. Am J Gastroenterol 88:1860-1864, 1993Google Scholar
  19. 19.
    Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB: Susceptibility of Campylobacter pylori to macrolides and flouroquinolones. J Antimicrobial Chemother 22:631-636, 1988Google Scholar
  20. 20.
    Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Simoni P, et al: Short-term, low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 6:773-777, 1994Google Scholar
  21. 21.
    Lind T, Veldhuyzen van Zanten SJO, Unge P, Spiller RC, Bayerdorffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C, Idstrom J-P: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH 1 Study. Helicobacter 1:138-144, 1996Google Scholar
  22. 22.
    Xia HX, Daw MA, Sant S, Beattie S, Keane CT, O'Morain CA: Clinical efficacy of triple therapy in Helicobacter pylori-associated duodenal ulcer. Eur J Gastroenterol Hepatol 5:141-144, 1993Google Scholar
  23. 23.
    Xia HX, Daw MA, Keane CT, O'Morain CA: The prevalence of metronidazole-resistant Helicobacter pylori in Irish dyspeptic patients. Ir J Med Sci 162:91-94, 1993Google Scholar
  24. 24.
    Xia HX, Keane CT, Beattie S, O'Morain CA. Standardisation of disc diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 38:2357-2361, 1994Google Scholar
  25. 25.
    Xia HX, Buckley M, Keane CT, O'Morain CA: Clarithromycin resistance in Helicobacter pylori: Prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 37:473-481, 1996Google Scholar
  26. 26.
    Unge P, Berstad A: Pooled analysis of anti-Helicobacter pylori treatment regimens. Scand J Gastroenterol 31(suppl 220):27-40, 1996Google Scholar
  27. 27.
    European Study Group on Antibiotic Susceptibility of Helicobacter pylori: Results of a multicentre European Survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 11:777-781, 1992Google Scholar
  28. 28.
    Becx MCJM, Janssen AJHM, Clasener HAL, de Koning RW: Metronidazole-resistant Helicobacter pylori. Lancet 335:539-540, 1990Google Scholar
  29. 29.
    Glupczynski Y, Burette A, de Koster E, Nyst JF, Deltenre M, Cadranel S, Bourdeaux L, de Vos D: Metronidazole resistance in Helicobacter pylori. Lancet 335:976-977, 1990Google Scholar
  30. 30.
    Rautelin H, Seppala K, Renkonen O-V, Vainio U, Kosunen TU: Role of metronidazole resistance in therapy of Helicobacter pylori. infections. Antimicrob Agents Chemother 36:163-166, 1992Google Scholar
  31. 31.
    van Zwet AA, Thijs JC, Oom JAJ, Hoogeveen J, Duringshoff BL. Failure to eradicate Helicobacter in patients with metronidazole-resistant strains. Eur J Gastroenterol Hepatol 5:185-186, 1993Google Scholar
  32. 32.
    van Zwet AA, Thijs, de Vries WS, Schiphius J, Snijder JAM: In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori. Antimicrob Agents Chemother 38:360-362, 1994Google Scholar
  33. 33.
    Banatvala N, Davies GR, Abdi Y, Clements L, Rampton DS, Hardie JM, Feldman RA: High prevalence of Helicobacter pylori. metronidazole resistance in migrants to east London: Relation with previous nitroimodazole exposure and gastroduodenal disease. Gut 35:1562-1566, 1994Google Scholar
  34. 34.
    Weisblum B: Erythromycin resistance by ribosomal modification. Antimicrob Agents and Chemother 39:577-585, 1995Google Scholar
  35. 35.
    Versalovic J, Kibler K, Small S, Graham DY, Go MF: Mutations in the 23S ribosomal RNA confer clarithromycin resistance in Helicobacter pylori. Gut 37(suppl 1):A67, 1995Google Scholar
  36. 36.
    Hultén K, Engstrand L: Acquired and persistent macrolide resistance in patients treated with clarithromycin. Gut 39(suppl 2):A8, 1996Google Scholar
  37. 37.
    Moayyedi P, Sahay P, Tompkins DS, Axon ATR: Efficacy and optimum dose of omeprazole in a new one-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 7:835-840, 1995Google Scholar
  38. 38.
    Yousfi MM, El-Zimaity HMT, Al-Assi MT, Cole RA, Genta RM, Graham DY: Metronidazole, omeprazole and clarithromycin: An effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 9:209-212, 1995Google Scholar
  39. 39.
    de Boer W, Driessen W, Jansz A, Tytgat G: Effect of acid suppression on efficacy of treatment for Helicobacter pylori. Lancet 345:817-820, 1995Google Scholar
  40. 40.
    Cayla R, Zerbib F, de Mascare F, Megraud F, Lamouliatte H: Dual therapy with high dose of omeprazole versus triple therapy using omeprazole in combination with two antibiotics for H. pylori eradication. Am J Gastroenterol 89:1366, 1994 (abstract)Google Scholar
  41. 41.
    Tham TCK, Collins JSA, McCormick C, Sloan JM, Bamford K, Watson RGP: Randomised controlled trial of ranitidine and omeprazole and their combination with antibiotics in the eradication of Helicobacter pylori. Gastroenterology 108:A240, 1995 (abstract)Google Scholar
  42. 42.
    Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyebi W, Bolton GH, Jones PH, Brown C: Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 9:41-46, 1995Google Scholar
  43. 43.
    Lamouliatte H, Cayla R, Zerbib F, Megraud F: Triple therapy with proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori eradication. Gastroenterology 108:A143, 1995 (abstract)Google Scholar
  44. 44.
    Harris A, Misiewicz JJ: Hitting H. pylori for four. Lancet 345:806-807, 1995 (commentary)Google Scholar
  45. 45.
    Vautier G, Scott BB: A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. Aliment Pharmacol Ther 11:107-108, 1997Google Scholar
  46. 46.
    Malfertheiner P, Megraud F, O'Morain C, Bell D, Porro GB, Deltenre M, Forman D, et al: Current European concepts in the management of H. pylori infection—The Maastricht Consensus Report. Eur J Gastroenterol Hepatol 9:1-2, 1997Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • Martin J. M. Buckley
  • Hua-Xiang Xia
  • Denise M. Hyde
  • Conor T. Keane
  • Colm A. O'Morain

There are no affiliations available

Personalised recommendations